Core Laboratories CLB Business Acquisition Contingent Cash Consideration

Business Acquisition Contingent Cash Consideration at other companies

Willdan GroupWLDN

$2.81M—

GenpactG

$77.5M—

Willdan GroupWLDN

$2.81M—

Braze, Inc.BRZE

$0—

CBIZCBZ

$6.3M-78.7%

MarineMaxHZO

$383K—

Other financials

Income statement

See full

Revenue$121.8M-1.4%

Operating income$1.9M-57.3%

Net income-$789.0K-412%

EPS (diluted)-$0.02—

Balance sheet

See full

Cash & equivalents$22.8M+3.2%

Total debt$167.8M-6.8%

Total equity$268.9M+6.1%

Total assets$587.7M+0.3%

Cash flow

See full

Operating cash flow$4.0M-40.5%

CapEx$3.4M+23.8%

Free cash flow$517.0K-86.7%

Valuation

See full

Market cap$537.03M-4.5%

Enterprise value$682.05M-3.9%

P/E18.5×-0.5×

P/S1×-0.1×

Profitability

See full

Operating margin10.3%-0.2pp

Net margin5.5%+0.1pp

FCF margin4.3%-4.6pp

Returns & leverage

See full

Return on equity11.1%-0.4pp

Debt / equity0.6×-0.1×

Current ratio2×-0.2×

Where this comes from

Reported directly by Core Laboratories in its filing.

Tagged under the XBRL concept clb:BusinessAcquisitionContingentCashConsideration.

The official record: Core Laboratories’s 10-K, filed March 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about Core Laboratories's business acquisition contingent cash consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Core Laboratories's business acquisition contingent cash consideration?: Core Laboratories (CLB) reported business acquisition contingent cash consideration of $1.02M in Q4 2025.
What does business acquisition contingent cash consideration mean?: Reflects cash payments made to satisfy earn-out provisions or performance-based milestones from previous business acquisitions. This metric helps investors assess the ultimate cost and performance outcomes of the company's inorganic growth strategy.